Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

The need for extended venous thromboembolism (VTE) treatment beyond 3 to 6 months is
usually determined by balancing the risk of recurrence if treatment is stopped against the …

Background New diagnosis, risk stratification, and treatment strategies became recently
available for patients with acute pulmonary embolism (PE) leading to changes in clinical …

Similar trends of management and in-hospital mortality of acute pulmonary embolism (PE)
have been reported in European and American populations. However, these tendencies are …

Introduction COVID‐19 predisposes patients to a higher risk of venous thromboembolism
(VTE), although the extent of these implications is unclear and the risk of bleeding has been …

Background Studies suggest that the direct factor Xa inhibitor rivaroxaban compared to
warfarin reduces the risk of post‐thrombotic syndrome (PTS) after deep vein thrombosis …

Introduction Availability of new treatment strategies for patients with acute pulmonary
embolism (PE) have changed clinical practice with potential influence in short-term patients' …

Abstract Background The XALIA and XALIA‐LEA prospective, noninterventional studies
investigated the safety and effectiveness of rivaroxaban versus standard anticoagulation for …

There is limited data on the bleeding safety profile of direct oral anticoagulants, such as
rivaroxaban, in low-and middle-income country settings like Kenya. In this prospective …

Los anticoagulantes orales directos han surgido como una de las herramientas que ha
cambiado el manejo de la enfermedad trombótica en los últimos 15 años. Sus ventajas …